Annals of oncology : official journal of the European Society for Medical Oncology

The most recent articles from: Ann. Oncol. July 2016

Ann. Oncol. · Jul 2016

Multicenter Study

Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.

Trastuzumab emtansine (T-DM1) exhibited enhanced antitumor activity when combined with docetaxel or pertuzumab in preclinical studies. This phase Ib/IIa study assessed the feasibility of T-DM1 + docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and T-DM1 + docetaxel ± pertuzumab in patients with HER2-positive locally advanced breast cancer (LABC). ⋯ NCT00934856.

read more… or not…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.